Chase LoPriore, a Director and VP of Corporate Development at Hepion Pharmaceuticals, Inc., filed a statement of changes in beneficial ownership on October 27, 2026, reporting the acquisition of stock options dated October 23, 2026.

Key Highlights

  • Reporting person: Chase LoPriore, identified as both a Director and VP of Corporate Development at Hepion Pharmaceuticals, Inc.
  • Options granted: 1,530,000 stock options acquired on October 23, 2026, with an exercise price of $0.14 per share.
  • Vesting schedule: According to the filing, 127,500 options vest in equal amounts monthly over 12 months from the date of grant.
  • Expiration date: The options are set to expire on October 23, 2036, per the filing.
  • Price of derivative security: The filing states the price of the derivative security is $0.
  • Post-transaction holdings: Following this transaction, LoPriore beneficially owns 2,875,500 derivative securities, as reported in the filing.

LoPriore's October 2026 Option Grant at Hepion Pharmaceuticals

According to the filing, Chase LoPriore, who serves as both a Director and VP of Corporate Development at Hepion Pharmaceuticals, Inc. (OTC:HEPA), reported the acquisition of 1,530,000 stock options on October 23, 2026. The options carry an exercise price of $0.14 and are exercisable into common stock of Hepion Pharmaceuticals, a biopharmaceutical company. The transaction code recorded in the filing is "A," indicating an acquisition of derivative securities.

The filing discloses that 127,500 of the granted options vest in equal monthly amounts over a 12-month period beginning on the date of grant. The options are set to expire on October 23, 2036, providing a ten-year window from the grant date. The stated price of the derivative security is $0, and the underlying security is common stock, with 1,530,000 shares underlying the options. Following this transaction, LoPriore's total beneficial ownership of derivative securities is reported as 2,875,500. The ownership form is listed as direct.

The filing was signed by Chase LoPriore on October 27, 2026, and was filed individually rather than as part of a joint or group filing. No amendment date was indicated, suggesting this is an original filing rather than a revision of a prior submission.

What Was Disclosed

The filing reported the grant of 1,530,000 stock options to Chase LoPriore, VP of Corporate Development and Director at Hepion Pharmaceuticals, Inc. (OTC:HEPA), at an exercise price of $0.14, with monthly vesting over 12 months and expiration on October 23, 2036.